CEO changes at Basking, Newleos, Valitor, Mosaic, Generation Bio
Plus management moves at CytomX, Recordati, ConcertAI, Amphista, Abeona, Achieve, Cartesian, Climb Bio and Amarin
As Basking Biosciences Inc. reached a clinical milestone for its acute ischemic stroke therapy, the biotech said Julia Owens will be its new CEO. The former CEO of Ananke Therapeutics Inc. and Millendo Therapeutics Inc. will succeed Richard Shea, who will become president and COO. This week’s start of Part B of Basking’s Phase II study of reversible thrombolytic therapy BB-031 triggered the company’s receipt of the $27.5 million second tranche of its $55 million series A funding, led by Arch Venture Partners and announced in January 2024.
Founding President and CEO David Donabedian of neuropsychiatry play Newleos Therapeutics Inc. is handing off his positions to Timothy Noyes, the former CEO of Aerovate Therapeutics Inc. Donabedian, an executive partner with early Newleos investor Longwood Fund, will be a company adviser. Newleos raised $93.5 million in a series A round announced in February...